C4X Discovery Holdings PLC Exercise of Options, Issue of Equity and TVR (8145J)
August 18 2023 - 7:45AM
UK Regulatory
TIDMC4XD
RNS Number : 8145J
C4X Discovery Holdings PLC
18 August 2023
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Exercise of Options, Issue of Equity and Total Voting Rights
18 August 2023 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, announces it has issued 107,500
ordinary shares of 1p each in the Company ("New Ordinary Shares")
following the exercise of options by certain employees of the
Company.
Admission and Total Voting Rights
Application has been made for the 107,500 New Ordinary Shares to
be admitted to trading on AIM and dealings are expected to commence
on or around 8.00 a.m. on 24 August 2023. The New Ordinary Shares
will rank pari passu with the existing ordinary shares.
Total Voting Rights
Following the issue of the New Ordinary Shares, the Company's
issued share capital now consists of 252,227,097 ordinary shares.
Accordingly, the figure of 252,227,097 may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in the Company under the FCA's Disclosure
Guidance and Transparency Rules.
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company,
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines. We
have a highly valuable and differentiated approach to Drug
Discovery through our enhanced candidate molecule design and
patient stratification capabilities, generating small molecule drug
candidates across multiple disease areas focused on
immuno-inflammation. Our commercially attractive portfolio ranges
from early-stage target opportunities to late-stage Drug Discovery
programmes and we have three commercially partnered programmes with
one candidate in clinical development.
For more information visit us at www.c4xdiscovery.com or follow
us on twitter @C4XDiscovery.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEDZGMRMRDGFZM
(END) Dow Jones Newswires
August 18, 2023 07:45 ET (11:45 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Aug 2024 to Sep 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Sep 2023 to Sep 2024